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Abstract
Aim: Obstructive	sleep	apnoea	(OSA)	is	frequent	in	type	2	diabetes	(T2D).	The	aim	
was to investigate the effect of a 12-week treatment with continuous positive airway 











0.8	mmol/mol	 (0.08%;	P	 =	 .6)	 in	 the	 control	 group	 (intergroup	 difference,	P	 =	 .6).	
Fasting	blood	glucose	increased	by	0.2	mmol/L	(P	=	.02)	in	the	CPAP	group	and	by	
0.4	mmol/L	(P	=	.01)	in	the	control	group	(intergroup	difference,	P	=	.7).	In	a	prespeci-
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1  | INTRODUC TION
Obstructive	sleep	apnoea	 (OSA)	 is	characterized	by	 recurrent	epi-
sodes	of	apnoea	(interruption	in	airflow	for	at	least	10	seconds)	and/





increases airflow which leads to a decreased number of airway col-
lapses,	thereby	improving	the	effective	sleep	time	and	sleep	quality.
During	 recent	 years,	 a	 remarkably	 high	 prevalence	 of	 OSA	 is	
documented in people with type 13	and	type	2	diabetes	(T2D).	The	




Sleep	 fragmentation	and	 intermittent	hypoxia	 are	hallmarks	of	
OSA.	It	has	previously	been	shown	that	insulin	sensitivity	is	compro-
mised	when	circadian	rhythm—for	example	induced	by	OSA—is	dis-
turbed9	and	short-term,	intermittent	hypoxia	is	induced10 in healthy 
subjects.	Hypoxia	results	in	increased	insulin	resistance	and	popula-
tion	studies	have	shown	that	OSA	is	independently	associated	with	





including two randomized controlled trials and four observational 
studies	 investigated	whether	CPAP	 treatment	 improves	 glycaemic	
control	and	insulin	sensitivity	in	people	with	OSA	and	T2D.	The	au-
thors	concluded	 that	CPAP	did	not	 improve	 the	glycaemic	control	
accessed	by	HbA1c	levels	but	may	improve	insulin	sensitivity.	In	two	






detailed	 than	with	HbA1c.	This	 is	useful	especially	 at	night	where	
the	 intervention	 treatment	 takes	 place.	 In	 all,	 four	 studies	 used	
CGM;	Babu	et	al14 and Guo et al18 reported a significantly reduced 
mean	glucose	and	reduced	GV	after	CPAP	use.	Dawson	et	al15 also 
demonstrated a reduced mean glucose but no significant change in 
variability.	A	more	recent	study	from	2017	by	Morariu	et	al19 showed 
no	change	in	mean	glucose	measured	by	CGM	after	CPAP	use.	GV	





2  | PARTICIPANTS AND METHODS
2.1 | Design
We performed a randomized controlled multicentre study of interven-
tion	with	CPAP	treatment	vs	no	CPAP.	The	treatment	period	included	
12	weeks	intervention	with	a	subsequent	9-month	open	extension.
The primary end-point of the study was change in carotid-femo-
ral	pulse	wave	velocity	(to	be	reported	elsewhere),	and	power	calcu-
lations and sample size calculations were based hereupon. The main 











cated’ T2D are attending a hospital-based outpatient clinic. Subjects 
who	 agreed	 to	 participate	 were	 screened	 with	 the	 ApneaLink+® 
device	 (ResMed).	The	definition	of	 complicated	T2D	can	vary,	but	
in	Denmark,	complicated	T2D	is	loosely	defined	as	T2D	with	multi-
ple late diabetic complications or/and glycaemic dysregulation (high 
Hba1c	or	problems	with	hypoglycaemia).
Inclusion	criteria	were	age	>18	years,	diagnosis	of	T2D	(accord-
ing	 to	WHO	criteria)	 for	at	 least	one	year,	OSA	defined	by	an	ap-
noea-hypopnoea	 index	 (AHI)	 >15	 events/h	 and	 signed	 informed	
consent.	 Exclusion	 criteria	 were	 contraindications	 to	 CPAP	 treat-
ment,	 other	 sleep	 breathing	 disorders	 (including	 central	 sleep	 ap-









K E Y W O R D S
continuous	glucose	monitoring,	continuous	positive	airway	pressure,	obstructive	sleep	
apnoea,	type	2	diabetes








eral practitioner to a sleep clinic can be up to 3 months in Denmark. 
Because	of	this,	we	considered	it	acceptable	to	enrol	subjects	 in	a	
3	months	study	period	before	initiation	of	CPAP	therapy.
2.3 | The ApneaLink®+ screening device
Pulse	 oximetry,	 nasal	 respiratory	 flow	 and	 thorax	 movements	
were	measured	with	the	ApneaLink®+	device	(ResMed),	that	uses	
the	same	algorithm	as	its	predecessor	ApneaLink®.20 Participants 
were instructed by trained study coordinators who provided them 
with oral and written instructions on how to mount the device at 
bedtime.	After	one	night's	sleep,	the	equipment	was	returned	to	
the clinic. Data were downloaded and analysed automatically by 
computer software. Only data available for more than four hours 
were	accepted	for	the	diagnosis.	Apnoea	was	defined	as	interrup-
tion in airflow for at least 10 seconds and hypopnoea as a decrease 
in	airflow	for	at	least	10	seconds	combined	with	≥3%	desaturation	
compared to pre-event baseline during sleep.1	 The	 frequency	of	
obstructive	events	 is	 reported	as	an	 index	based	on	the	average	





vestigators with information on the results of the screening. Patients 
with	moderate	or	severe	OSA	were	invited	to	participate	in	the	main	
study	 if	 all	 inclusion	 and	 no	 exclusion	 criteria	 were	met.	 Possible	
candidates were provided with information about the study and ap-
propriate time to consider their participation was given. Participants 




CGM	 was	 performed	 using	 a	 blinded	 CGM	 (iPro2	 [Medtronic])	
with	 an	 Enlite	 sensor	 (Medtronic)	 for	 six	 consecutive	 days	 before	
randomization and at the end of the 12-week intervention period. 
Participants were instructed to complete at least four blood glu-
cose measurements per day with the provided blood glucose meter 
Contour	 XT	 (Bayer).	 The	 data	 from	 the	 sensor	 were	 downloaded	
using	 Medtronics	 Carelink	 iPro.	 The	 downloaded	 data	 contained	







ability,	 a	measure	of	oscillations	 in	blood	glucose	 levels	 (24	hours,	
daytime	and	night-time).	CGM	data	covering	at	least	75%	of	the	sen-
sor time were considered sufficient.16
2.5 | Clinical investigations
Fasting blood samples were collected from the patients before and 
after	 the	 intervention	 including	 HbA1c	 (analysed	 by	 high	 perfor-
mance	 liquid	 chromatography),	 blood	 glucose,	 plasma	 total-,	HDL-	
and	LDL-cholesterol,	and	creatinine.	Overnight	urine	samples	were	
collected to measure albumin and creatinine.
Clinical measures were collected at baseline and after 12 weeks 
including	hip,	waist	and	neck	circumferences	(measured	at	the	widest	
point),	 body	weight	 and	 height	 and	 blood	 pressure	measured	 twice	
by	an	oscillometric	method	(Microlife	WatchBP	Office,	Microlife	AG).
2.6 | Diabetic complications
Nephropathy was defined as microalbuminuria (urinary albumin/
creatinine	ratio	30-299	mg/g)	or	macroalbuminuria	(urinary	albumin/
creatinine	ratio	≥300	mg/g).
Peripheral neuropathy was diagnosed based on monofilament 
testing,	classifying	peripheral	neuropathy	as	lack	of	sensation	in	at	
least two out of three touches. Test of vibration sensation was not 
done	on	all	sites.	Therefore,	the	monofilament	data	were	reported.
Signs of autonomic neuropathy were investigated in the fasting 
state	by	the	Vagus™	device	(Medicus	Engineering	Aps)21 which ob-
tains an electrocardiogram recording by two handhold electrodes 
during rest and three active tests. One abnormal test is indicative 





Epworth	Sleepiness	Scale	 (ESS)	measures	daytime	sleepiness23 on a 
scale	from	0	to	24.	The	total	score	is	calculated	from	8	questions	rating	
the chances of dozing off or falling asleep in eight different situations 
commonly	encountered	in	daily	life.	A	score	above	10	is	abnormal	and	
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2.8 | Intervention










tiation	 of	 the	CPAP	 therapy.	Different	mask	 types—full	 face	 or	 nasal	
mask—in different sizes were fitted to the participants until treatment 
was	well-tolerated.	Good	compliance	to	the	CPAP	device	was	defined	as	
a	minimum	usage	of	four	hours	per	night	for	at	least	70%	of	all	nights.25
Participants randomized to the control group were invited to fol-
low-up visits after 1 month and after 12 weeks or order to follow the 
same protocol as the intervention group. The control group received 
no	treatment	other	than	recommendations	on	sleep	hygiene.	All	par-





groups	 at	 baseline—including	 CGM	 variables—were	 performed	 with	




groups	of	different	CGM	variables	using	Student's	 t test. Calculations 















screening	 for	 OSA	 (Figure	 1).	 Among	 these,	 38	 patients	 (8%)	
were unable to complete the overnight registration due to mis-
understanding of instructions or discomfort with the device and 
were	therefore	not	included.	Hence,	420	participants	completed	






excluded	 due	 to	 low	C-peptide	 or	 low	HbA1c,	 heart	 failure,	 atrial	
fibrillation	or	uncontrolled	hypertension.	A	total	of	72	participants	
were	randomized,	65	of	them	completed	the	12-week	intervention,	
six	 patients	 discontinued	 the	 study	 primarily	 due	 to	 incompatibil-
ity	 to	 the	CPAP	device	 and	 one	 patient	 in	 the	 control	 group	 died	
unexpectedly	(Figure	1).	The	baseline	characteristics	of	the	72	par-
ticipants are presented in Table 1. Participants were predominantly 
male,	 and	 at	 baseline	 characteristics	 were	 comparable	 between	
the	 intervention	and	the	control	group,	except	for	BMI	which	was	
significantly higher in the intervention group. There were no dif-
ferences in baseline characteristics between the participants who 





had an ESS above 10 points.
3.2 | CPAP treatment
The	average	use	of	the	CPAP	device	was	5.6	±	1.9	hours	per	night.	
Good	 compliance	 was	 obtained	 by	 16	 participants	 (44%),	 that	 is	
they	used	CPAP	for	more	than	4	hours	more	than	70%	of	the	nights.	
In	 the	 last	month	 of	 the	 CPAP	 intervention,	 the	 average	 use	was	
5.4	±	2.1	hours	per	night	and	during	this	period	15	participants	(42%)	






pressure,	HbA1c,	 laboratory	 values,	 ESS	 and	AHI,	 except	 for	BMI	
which	was	still	significantly	higher	in	the	compliant	CPAP	group.
3.3 | AHI and ESS












baseline and another two participants after the 12 weeks’ interven-
tion,	hence	 the	different	number	of	participants	 in	Tables	2,	3	and	
4. No difference between the two groups was observed at baseline 
for	any	of	the	CGM	derived	data.	Similarly,	no	differences	between	
groups	after	intervention	in	mean	glucose	(24	hours,	day	and	night),	
different	measures	of	 being	 in/out	 of	 range	or	GV	were	observed.	
The	ANCOVA	analysis	 adjusted	 for	 baseline	BMI,	HbA1c,	AHI	 and	
baseline value of the dependent variable did not show statistically 
significant	effects	on	glycaemia	during	CPAP	treatment	(Tables	2,	3	
and	4).
The prespecified subgroup analysis on the fully compliant par-
ticipants	 did	 not	 differ	 from	 the	main	 findings,	 although	 these	16	
participants had a tendency towards better glycaemic indices 
during	 night.	 Change	 in	 average	 glucose	 night-time:	 CPAP	 group	
−0.7	 ±	 1.9	mmol/L	 vs	 control	 group	 +	 0.6	 ±	 2.3	mmol/L,	P	 =	 .07.	









in the two groups were not significantly different. When analysing 
only	compliant	CPAP	users,	HbA1c	in	the	CPAP	group	decreased	by	
0.4	mmol/mol	 (0.04%;	P	 =	 .9,	 paired	 t	 test).	 Fasting	blood	glucose	




Delta values of fasting blood glucose in the two groups were not 
significantly different.
Adjustments	of	 the	participants’	 blood	glucose	 lowering	medi-
cation	was	not	allowed	during	the	12	weeks	trial,	nevertheless	four	
patients	 in	 the	 CPAP	 group	 and	 two	 in	 the	 control	 group	 experi-
enced intensification of their treatment prescribed by their general 
practitioner.
F I G U R E  1  Patient	flow	chart.	The	screening	procedure	was	slightly	different	at	the	sites,	since	the	Aarhus	and	Silkeborg	investigators	
assessed	the	possible	participants	according	to	the	in-/exclusion	criteria	before	sending	out	letters
31 paents in the control group 
with baseline CGM




176 possible parcipants 
(moderate to severe OSA)
97 signed informed 
consents
31 paents with follow-up CGM
72 randomized with baseline 
characterisc
34 paents in the CPAP group 
with baseline GCM
• 148 mild OSA
• 96 no OSA
• 38 no examinaon 
• 71 does not meet 
in/exclusions criteria
• 25 screen failures
• 5 paents without CGM
• 2 with insufficient baseline CGM 
(control group)
• 4 drop outs no follow-up CGM (CPAP 
group)
• 1 paent died (control group) 
• 2 with insufficient follow-up CGM
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n = 36 P-value
Male	sex	% 72% 83% .26
Age	(y) 63	±	7 61	±	8 .24
Duration	of	diabetes	(y) 16	±	7 16	±	10 .97
Height	(m) 1.74	±	0.09 1.73	±	0.07 .72
Body	weight	(kg) 109	±	16 99	±	11 .004
Body	mass	index,	BMI	(kg/m2) 36.1	±	4.7 33.1	±	3.5 .003
Waist	circumference	(cm) 119	±	17 115	±	8 .21
Hip	circumference	(cm) 118	±	12 112	±	11 .02
Neck	circumference	(cm) 47	±	14 44	±	3 .25
Systolic	blood	pressure	(mm	Hg) 141	±	15 141	±	16 .98
Diastolic	blood	pressure	(mm	Hg) 81	±	9 82	±	8 .47
Sleep related data
Epworth	Sleepiness	Scale	(ESS) 7	±	3 8	±	5 .24
Apnoea-hypopnoea	index	(AHI) 32	(IQR	21-43) 34(IQR	22-49) .62
Laboratory	values
HbA1c	(mmol/mol) 64	±	9	(8.0	±	0.8) 65	±	9	(8.1	±	0.8) .81
Plasma	fasting	glucose	(mmol/L) 10.0	±	2.6 9.1	±	2.1 .11
Plasma	creatinine	(µmol/L) 85.5	±	35.0 83.6	±	20.2 .77
Plasma	total-cholesterol	(mmol/L) 4.2	±	0.9 3.9	±	0.9 .26
Plasma	LDL-cholesterol	(mmol/L) 2.1	±	0.8 1.8	±	0.7 .16
Plasma	HDL-cholesterol	(mmol/L) 1.17	±	0.24 1.16	±	0.35 .89
Lifestyle
Alcohol	consumption	per	week	(0-7	units,	8-21	units,	>21	units) 84%/8%/8% 89%/11%/0% .20
Current	smokers,	n	(%) 3	(8%) 7	(19%) .38
Late	diabetic	complications
Nephropathy






Established	CANa  43% 38% .45
Peripheral	neuropathy,	n	(%) 5	(14%) 3	(8%) .43
Cardio	vascular	disease	(n) AMI	=	2 AMI	=	3 –
TCI = 6 TCI = 4 –
Use of medication
Metformin 83% 78% .55
Other	oral	antidiabetic	drugs	(DPP-4/SGLT-2/SU) 23% 31% .69
Insulin 61% 69% .46
GLP-1	agonist 58% 50% .48
Antihypertensive	treatment 94% 83% .13
Diuretics 58% 47% .35
Statin treatment 79% 83% .59
Aspirin 53% 51% .91
aCardiovascular autonomic neuropathy. 
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3.6 | Blood pressure and BMI











pants had a tendency towards better glycaemic indices. The results 
from the subgroup analyses are with reservations since a limited 
number of participants are included in the analyses.
There are four previous prospective trials investigating the ef-
fect	of	CPAP	treatment	on	glycaemic	control	evaluated	by	CGM	in	
people with T2D.14,15,18,19	In	general,	these	studies	have	limitations	
like	 absence	 of	 a	 control	 group,	 a	 limited	 number	 of	 participants	
and	short	duration	of	CPAP	treatment.	Thus,	Babu	et	al,14 Dawson 
et al15 and Guo et al18	studied	the	effect	of	CPAP	treatment	for	83,	
41	and	30	days,	respectively,	in	25,	20	and	40	patients	and	all	three	
studies were without a control group. They all demonstrated im-
provements	 in	CGM	 indices	after	CPAP	 treatment.	A	more	 recent	




to the treatment was challenging and only 16 of the 36 participants 
(44%)	 randomized	 to	 the	 intervention	 had	 good	 compliance.	 Our	
participants	did	not	feel	sleepy	at	baseline	(ESS	score	was	below	10)	
which	could	be	one	explanation	for	the	low	compliance.	Former	stud-
ies27,28	 shows	 conflicting	 results	 when	 comparing	 adherent	 CPAP	
users with nonadherent in terms of ESS values. Kohler et al27 found 
that ESS was not associated with long-term compliance whereas 
Jacobsen et al28 found that ESS was independently associated with 
CPAP	 adherence.	 Lack	 of	 compliance	 to	 CPAP	 treatment	 is	 not	 a	




present	 study.	 Therefore,	 low	 adherence	 is	 a	 general	 limitation	of	
CPAP	therapy.	In	a	study	by	Mokhlesi	et	al30 found that one week of 
CPAP	use,	in	average	7.9	hours,	improved	24-hour	profile	of	glucose;	
however,	this	study	was	performed	in	laboratory	which	makes	it	dif-
ficult comparing it with studies that have longer time of duration and 
where	CPAP	treatment	takes	place	at	home.	Babu	et	al,14 Dawson 
et al15 and Guo et al18	all	report	daily	CPAP	use	from	4.2	±	2.9	hours	
TA B L E  3  Continuous	glucose	monitoring	data	(CGM)	only	in	the	compliant	CPAP	users,	defined	as	a	minimum	usage	of	4	h	per	night	for	
at	least	70%	of	all	nights














n = 16 control = 29
P-
value
Time	with	CGM-	data	(%) 97.1	±	7.5 98.8	±	2.2 1.7	±	7.9 .4 2.8 .2
Average	glucose,	24	h	(mmol/L) 9.9	±	2.0 9.5	±	1.1 −0.4	±	1.7 .3 −0.9 .2
Average	glucose,	night	(mmol/L) 9.5	±	2.3 8.9	±	1.2 −0.7	±	1.9 .2 −1.3 .07
Average	glucose,	day	(mmol/L) 10.1	±	2.0 9.7	±	1.1 −0.4	±	1.7 .4 −0.9 .2
Time	in	range	(3.9-10.0	mmol/L;	%)
24 h 59.2	±	22.3 64.3	±	17.4 5.1	±	16.0 .2 11.7 .1
Night 62.2	±	28.8 69.5	±	21.3 7.3	±	21.3 .2 14.7 .08
Day 57.4	±	20.5 61.4	±	17.7 4.0	±	17.3 .4 10.2 .2
Glucose	<3.9	mmol/L	(%	of	time) 0.9	±	1.8 0.2	±	0.6 −0.6	±	1.7 .1 −0.5 .5
Hypoglycaemic	episodes	(no.)b  0.6	±	1.2 0.3	±	0.7 −0.3	±	0.9 .2 −0.04 1.0
Glucose	>10.0	mmol/L	(%	of	time) 40.0	±	22.8 35.5	±	17.4 −4.5	±	16.5 .3 −11.2 .2
Glucose	>13.9	mmol/L	(%	of	time) 12.6	±	17.6 7.0	±	7.7 −5.6	±	15.5 .2 −8.6 .1
Glycaemic variability
CV,	24	h 0.27	±	0.06 0.25	±	0.06 −0.02	±	0.04 .1 −0.02 .6
CV,	night 0.24	±	0.08 0.22	±	0.09 −0.01 .5 −0.16 .5
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per	night	to	5.8	±	1.0	hours	per	night	which	is	comparable	with	the	
results from this study.
A	review	from	2016	by	Martínez-Cerón	et	al31 and another review 
by	Labarca	et	al32	 from	2018	 investigated	the	effect	of	CPAP	treat-
ment	on	glucose	metabolism	in	patients	with	OSA,	both	participants	
with diabetes and without. Glucose metabolism was evaluated by 
HbA1c	 levels,	calculation	of	homeostatic	model	assessment	of	 insu-
lin	resistance	(HOMA-IR)	index	or	by	hyperinsulinaemic	euglycaemic	
clamps.	The	conclusion	was	 indecisive	 in	the	Martínez-Cerón	et	al31 
study	 and	 in	 the	 Labarca	 et	 al32	 study	 showed	 that	CPAP	does	not	
improve	glycaemic	control	in	respect	to	HbA1c	and	fasting	glucose.
The	lack	of	effect	of	CPAP	on	glycaemic	 indices	 in	the	present	
study	 is	 surprising	 since	 CPAP	 therapy	 of	OSA	 is	 associated	with	
a	 reduction	 in	 sympathetic	 nervous	 system	 (SNS)	 overactivity.33 
Activation	 of	 the	 SNS	 should	 theoretically	 lead	 to	 a	 higher	 blood	
glucose concentration via stress hormones (eg cortisol and adren-
aline)	secreted	during	apnoea	periods.	Therefore,	when	the	activity	




three	 of	 four	 patients	 in	 the	 CPAP	 group	 had	 signs	 of	 autonomic	





between	 the	control	group	and	 the	CPAP	group.	The	 tendency	of	
effect	of	CPAP	on	the	CGM-derived	glycaemic	variables	in	the	com-
pliant	group	supports	this.	Moreover,	it	cannot	be	excluded,	that	par-






Our study has several strengths. It is the largest prospective ran-
domized	controlled	trial	with	a	study	period	of	12	weeks,	being	lon-
ger	than	in	previously	studies	to	date.	The	high-quality	CGM	data16 
which allowed us to have detailed information about both daytime 
and	night-time	fluctuations	instead	of	only	HbA1c	and	fasting	blood	
glucose is also a strength.




Regression coefficient (95% CI)
P-value
Regression coefficient (95% CI)
P-value
Effect of CPAP vs control 
control = reference
Effect of CPAP vs control 
adjusted for baseline Hba1c, 
AHI, BMI and dependent 
variable Control = reference
All	58	participants
Average	CGM	glucose,	24	h	(mmol/L) −0.7	(−1.8	to	0.4) .22 −0.8	(−1.7	to	0.2) .10
Average	CGM	glucose	night	(mmol/L) −0.7	(−1.8	to	0.4) .21 −0.5(−1.5	to	0.4) .27
Average	CGM	glucose	day	(mM) −0.7	(−1.8	to	0.5) .25 −0.9	(−1.9	to	0.1) .08
Time	in	range	(3.9-10.0	mmol/L;	%)
24 h +6.6	(−6.2	to	19.3) .31 +	9.2	(−2.6	to	21.0) .12
Night +6.9	(−6.3	to	20.1) .30 +	5.5	(−7.0	to	18.0) .38
Day +6.3	(−7.8	to	20.4) .37 +	10.8	(−2.0	to	23.6) .10
Glycaemic	variability,	coefficient	of	variation −0.008	(−0.05	to	0.03) .69 −0.005	(−0.03	to	0.04) .77
dCPAP	noncompliant	participants	excluded
Average	CGM	glucose,	24	h	(mmol/L) −1.0	(−2.3	to	0.4) .15 −0.5	(−1.7	to	0.7) .40
Average	CGM	glucose	night	(mmol/L) −1.2	(−2.6	to	0.1) .07 −0.1	(−1.2	to	1.0) .86
Average	CGM	glucose	day	(mmol/L) −0.9	(−2.2	to	0.5) .21 −0.6	(−1.9	to	0.6) .30
Time	in	range	(3.9-10.0	mmol/L;	%)
24 h +11.7	(−3.4	to	26.7) .13 +	8.8	(−5.7	to	23.3) .23
Night +14.7	(−1.8	to	31.2) .08 +	3.3	(−11.8	to	18.4) .66
Day +10.2	(−6.0	to	26.4) .21 +	11.1	(−4.4	to	26.6) .16
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did	 not	 change	 our	 results.	 Low	 adherence	 to	 CPAP	 is	 common	
which results in the relatively small number of compliant users. 
With	 a	 larger	 sample	 size,	 the	 tendency	 towards	 better	 glycae-
mic control overall and especially during night-time might have 
been	more	distinct.	Moreover,	 the	 study	was	not	blinded	 (ie	 the	
control	group	was	not	a	placebo	group	treated	with	sham	CPAP)	
since	sham	CPAP	treatment	is	difficult	to	apply	without	unblinding	
the participants. The inclusion of participants with only moderate 
to	 severe	OSA	 and	 T2D	makes	 it	 difficult	 to	 generalize	 to	 other	
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